[
  {
    "ts": null,
    "headline": "Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection",
    "summary": "NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting depot injectable treatments, today provided an update on the clinical development program for its cariprazine once monthly injection. The company has enrolled the first patient into a Phase I/II study evaluating the product. Mapi Pharma’s injectable version of cariprazine, developed using its patented D",
    "url": "https://finnhub.io/api/news?id=2694d7398e047071e4d6df5716461640afabd47dc7aa96546b838adef4ffc9fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758121200,
      "headline": "Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection",
      "id": 136789212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting depot injectable treatments, today provided an update on the clinical development program for its cariprazine once monthly injection. The company has enrolled the first patient into a Phase I/II study evaluating the product. Mapi Pharma’s injectable version of cariprazine, developed using its patented D",
      "url": "https://finnhub.io/api/news?id=2694d7398e047071e4d6df5716461640afabd47dc7aa96546b838adef4ffc9fd"
    }
  }
]